EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

EyePoint (Nasdaq: EYPT) will report first quarter 2026 financial results on May 6, 2026 and will host a conference call and live audio webcast at 8:30 a.m. ET to discuss results and recent corporate developments.

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) will report first quarter 2026 financial results on May 6, 2026 and will host a conference call and live audio webcast at 8:30 a.m. ET to discuss results and recent corporate developments.

Registration is required for the live call; a webcast replay will be available on the company website.

Argus Apr 29 session

-4.53% close to close Open Argus

Details

News Market Reaction – EYPT

On Apr 29, the day this news came out, EYPT closed 4.53% below the previous close.

Data tracked by StockTitan Argus for the Apr 29 session.

Key Figures

Earnings date: May 6, 2026 Earnings call time: 8:30 a.m. ET

Earnings date

May 6, 2026

Scheduled first quarter 2026 financial results release

Earnings call time

8:30 a.m. ET

Start time for Q1 2026 results conference call and webcast

Previous Earnings date Reports

1 past event · Latest: Feb 25

Same Type 1 event

1. Feb 25

   Earnings date notice

   24h Move

   +4.2%

   Announced timing of Q4 and full-year 2025 results and webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and highlight recent corporate developments.

To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/hjmg6gw2. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A webcast replay will also be available on the Company website at the conclusion of the call.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU^™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:

Green Room Communications 
Direct: 850-384-2833
EyePointMedia@grcomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will EyePoint (EYPT) report first quarter 2026 results and hold the webcast?

EyePoint will report Q1 2026 results and host a webcast on May 6, 2026 at 8:30 a.m. ET. According to EyePoint, the event will cover financial results and recent corporate developments and will include a live audio webcast and conference call.

How can investors register for the EyePoint (EYPT) May 6, 2026 conference call?

Investors can register for the live conference call using the company’s provided audio conference link. According to EyePoint, registration is required to access the live call and the link is available in investor communications and the company website.

Where will the EyePoint (EYPT) live audio webcast be available during the May 6, 2026 event?

The live audio webcast will be available in the Investors section of the company website during the event. According to EyePoint, a webcast replay will also be posted on the company website after the call concludes for later viewing.

Will EyePoint (EYPT) provide a replay of the May 6, 2026 earnings webcast?

Yes, a webcast replay will be posted on the company website after the call concludes. According to EyePoint, the replay will be accessible from the Investors section for those who cannot join the live audio webcast or conference call.

What topics will EyePoint (EYPT) cover during the May 6, 2026 conference call?

The call will present first quarter 2026 financial results and highlight recent corporate developments. According to EyePoint, management will discuss quarterly results and other material corporate updates during the live webcast and conference call.